Torrent Pharma

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Led by the India business and rest-of-the-world markets, the company reported a robust 14.3 per cent year-on-year (Y-o-Y) growth in revenues

Torrent Pharmaceuticals posted a 16% rise in Q2FY26 profit to Rs 591 crore, with double-digit growth across India, the US, and Brazil driving revenue higher.

Fair trade regulator CCI on Tuesday cleared Torrent Pharmaceuticals Ltd's proposed acquisition of a stake in JB Chemicals and Pharmaceuticals, subject to voluntary modifications offered by the companies. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in JB Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to the acquisition of shareholding by Torrent Pharmaceuticals Ltd (acquirer) in JB Chemicals & Pharmaceuticals Ltd (target) and the subsequent amalgamation of the target with the acquirer," the regulator said in a release. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. "The Commission approved the proposed combination subject to compliance with voluntary modifications offered by the parties (Torrent Pharmaceuticals Ltd and JB Chemicals & Pharmaceuticals Ltd)," it added. Torrent Pharmaceuticals is the ...

Analysts are optimistic on Torrent Pharma's growth after a solid Q1 FY26 report, with strong performance in Brazil and US generics despite currency volatility and German challenges

Torrent Pharmaceuticals on Monday said its consolidated net profit increased 20 per cent year-on-year to Rs 548 crore in the June quarter, driven by strong sales across markets, including India and the US. The drug firm reported a net profit of Rs 457 crore in the April-June quarter of the last fiscal. Revenue from operations rose to Rs 3,178 crore in the June quarter compared with Rs 2,859 crore in the year-ago period, Torrent Pharmaceuticals said in a statement. The drug maker said its India revenues rose by 11 per cent year-on-year to Rs 1,811 crore in the April-June period, led by outperformance in focus therapies. The US business revenues stood at Rs 308 crore in the June quarter, by 19 per cent year-on-year, it added. Similarly, revenue in Brazil rose by 11 per cent to Rs 218 crore, the company stated. Its sales in Germany were up 9 per cent year-on-year to Rs 308 crore in the June quarter against the same period last year. Shares of Torrent Pharma settled 0.75 per cent hi

Torrent Pharmaceuticals reports Rs 548 crore Q1 net profit, led by strong growth in India, the US, and Brazil, with chronic therapies and top brands driving momentum

Stocks to buy: Analyst at Angel One recommends Shyam Metalics and Torrent Pharma; Check target price, stop loss here

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Ahmedabad-based Torrent Pharmaceuticals has sought fair trade regulator CCI's clearance to acquire a majority stake in in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. After the completion of the deal, Torrent Pharmaceuticals will become India's second most valued pharma company. The development came after Torrent Pharmaceuticals in June this year announced the acquisition of a majority stake in J B Chemicals and Pharmaceuticals in a Rs 19,500-crore deal. "The proposed combination relates to acquisition of shareholding by the acquirer (Torrent Pharmaceuticals Ltd) in the target (J B Chemicals & Pharmaceuticals Ltd) and the subsequent amalgamation of the target with the acquirer," according to a notice filed with the Competition Commission of India (CCI). Torrent Pharmaceuticals is the flagship company of the Torrent group and is engaged in the business of manufacturing and sale of pharmaceutical formulations (FDFs) across therapeutic segments. J B Chemicals & ...

Despite steep premium and short-term earnings dilution, analysts expect Torrent Pharma's acquisition of JB Chemicals to be value accretive in the medium term

Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad

Torrent Pharma is negotiating to acquire JB Chemicals from KKR in a deal that may trigger an open offer, strengthening its position in the domestic pharma market

Torrent Pharma share price rose after JPMorgan reportedly upgraded the company to 'Overweight'. The brokerage also hiked the target price to ₹3,800, from ₹3,650 earlier.

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

Tausif Shaikh, India analyst for pharma and healthcare, BNP Paribas India, prefers domestic-focused companies like Torrent Pharmaceuticals, and JB Chemicals and Pharmaceuticals in the sector

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

The drug maker had reported a profit after tax (PAT) of Rs 443 crore in the October-December quarter of the last fiscal

A long build-up is seen in the Torrent Pharma Futures, where we have seen an 18 per cent rise in the open interest with prices rising by 2.5 per cent